Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients

Randomised, double-blind, placebo-controlled, single-centre Phase II study comparing single-dose oral psilocybin (25 mg) to placebo in patients with alcohol use disorder who have completed withdrawal treatment in the prior six weeks.

Primary outcomes assess effects on alcohol use behaviour and clinical symptoms; mechanistic outcomes include neurocognitive and emotional measures. The protocol includes six clinic visits over six weeks and follow-up surveys at 3 and 6 months.